HomeHypertensionVol. 47, No. 5Microvascular Plasticity and Experimental Heart Failure Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBMicrovascular Plasticity and Experimental Heart Failure Bernard I. Lévy Bernard I. LévyBernard I. Lévy From the Centre for Cardiovascular Research, Inserm Lariboisière, Paris, France. Search for more papers by this author Originally published27 Mar 2006https://doi.org/10.1161/01.HYP.0000215283.53943.39Hypertension. 2006;47:827–829Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: March 27, 2006: Previous Version 1 Angiogenesis is an essential process in adulthood during wound healing and restoration of blood flow to injured tissues. Angiogenesis is regulated by a very sensitive interplay of growth factors and inhibitors; their imbalance can lead to very diverse diseases. Excessive angiogenesis is involved in malignant, diabetic retinopathy and inflammatory disorders (eg, rheumatoid arthritis, psoriasis, atherosclerosis). Conversely, insufficient angiogenesis may underlie conditions such as ischemic heart diseases, stroke, hypertension, and diabetes. Hence, during the evolution of these degenerative pathologies, inadequate blood vessel growth and insufficient microvascular density leads to poor circulation and tissue suffering or, ultimately, necrosis and death.1In several physiological conditions, such as muscular exercise training and detraining, acclimatization to altitude, and aging, an adaptation of the microvascular network structure and function to new conditions has been reported.2,3 Interestingly, there is a close link between cerebral angiogenesis and learning; during cognitive decline in relation to senescence or degenerative cerebral diseases, microvascular density is decreased in specific cerebral areas. Specifically, there is a striking relationship between the capillary density, the cerebral tissue blood flow, the local glucose use, and other measures of neuronal signaling, such as the NA+/K+ ATPase (reviewed in Reference 4). Therefore, microvascular plasticity, defined as the ability of the arteriole and capillary network to adapt to the metabolic local conditions by proangiogenesis or antiangiogenesis processes, likely plays a key role in many tissue homeostatic processes.Microvasculature and Arterial HypertensionIn hypertension, the role of microcirculation (arteriolar and capillary) is of particular importance in increasing periph-eral resistance by decreasing the number of vessels per unit of tissue volume; a phenomenon known as “microvascular rarefaction.” Ruedemann,5 in 1933, was the first to describe microvascular rarefaction in the conjunctiva of hypertensive patients. Rarefaction has also been observed by other investigators in humans and in different tissues in the majority of experimental models of hypertension, particularly in the spontaneously hypertensive rat and the rat with Goldblatt hypertension. Experimental evidence suggests that microcirculatory rarefaction, which manifests as an increased intercapillary distance, is responsible for nonuniform tissue perfusion leading to hypoperfused and hypo-oxygenated areas in which oxygen partial pressure drops to extremely low values that can restrict metabolic activity.6 Capillary rarefaction in hypertensive patients has even been suggested to be one of the reasons for the defective response to an insulin injection in increasing glucose uptake and vasodilation.7Several mechanisms have been proposed to explain microvascular rarefaction. Prewitt et al8 were the first to make a distinction between functional rarefaction and structural rarefaction. The former would be because of excessive (but reversible) vasoconstriction, causing occlusion of resistance arterioles and nonperfusion of distal capillaries. Structural rarefaction would be because of the anatomic absence of certain arterioles and capillaries. It is highly likely that the first precedes the second: abnormally high vasomotor tone would initially lead to nonperfusion of some vessels, which would then involute and disappear. Indeed, it is well known that endothelial shear stress leads to sustained endothelial nitric oxide release. The absence of flow and, therefore, of nitric oxide would lead to apoptosis and loss of nonperfused vessels. This theory ties in directly with the theory of protecting the capillary bed from hypertension by abnormal vasoconstriction. According to this hypothesis, microcirculatory rarefaction would be a result of hypertension.Capillary Density and Oxygen Supply During Ventricular Hypertrophy and Cardiac FailureAlthough increased external load initially induces cardiac hypertrophy with preserved contractility, sustained overload eventually leads to heart failure through poorly understood mechanisms. Cardiac remodeling includes changes of both the myocytes and the extracellular matrix. Capillary density and spatial arrangement are important determinants in maintaining the balance between myocardial oxygen demand and supply. These indices may be seriously altered in patients with cardiac hypertrophy and heart failure.The diffusion of oxygen from capillaries to cardiomyocytes depends, among other determinants, on the arterial oxygen pressure, the flow through the capillaries, and on the distance between any 2 adjoining capillaries. The capillary density and the intercapillary distance are both altered in cardiac hypertrophy related to ischemic disease or dilated cardiomyopathy. In a recent work, by using quantitative histological measurements, Karcha et al9 evidenced that the mean diffusion distance increased from left ventricular myocardium from control to dilated cardiomyopathy and ischemic and inflammatory cardiomyopathies. Therefore, insufficient supply of oxygen to myocardial tissue may lead to chronic hypoxia and myocytes dysfunction.In the present issue of Hypertension, Izumiya et al10 report a fascinating experimental study: they showed that administration of a vascular endothelial growth factor (VEGF) trap reagent, able to block signaling of all VEGF isoforms, to mice subjected to pressure overload by surgical aortic constriction resulted in diminished cardiac hypertrophy and promoted the progression to heart failure. The same group had described previously in conditional transgenic mice by the sequential development of adaptive cardiac hypertrophy with preserved contractility in the acute phase and dilated cardiomyopathy in the chronic phase after the induction of an activated Akt1 gene in the heart.11 In this setting, coronary angiogenesis was enhanced during the acute phase of adaptive cardiac growth but reduced as hearts underwent pathological remodeling.In the present study, the authors provided evidence that inactivation of endogenous VEGF impaired adaptive cardiac hypertrophy in response to pressure overload and contributed to the rapid progression from compensatory cardiac hypertrophy to heart failure. This underlines the importance of microvascular plasticity to allow adaptation of the vascular network and, thus, the oxygen supply, to increased metabolic demand related to the pressure overload. Adapted microvascular plasticity allows compensatory cardiac hypertrophy. In the absence of such vascular plasticity because of VEGF blockade, myocardium hypertrophy is unable to develop, thereby contributing to the switch toward cardiac failure, that is, to cardiomyocytes in vivo ultimately becoming maladaptive (Figure). This important work raises at least 3 series of pathophysiological and clinical questions. First, is it possible and beneficial to stimulate expression of angiogenic growth factors in hypertensive cardiopathy to delay the occurrence of heart failure? If yes, how can this be achieved? Are conventional pharmacological treatments able to increase VEGF expression in the myocardium? Second, is it possible, by restoring the production of VEGF, to stabilize heart failure and even to reverse it? Third, antiangiogenic agents, such as bevacizumab, have been rationally designed to target VEGF in patients with metastatic colorectal cancer to block tumor angiogenesis. The side effect profile of bevacizumab has been evaluated and makes it a suitable adjunct to standard chemotherapy; it is now approved for use in the United States, the European Union, and other markets worldwide. However, the most commonly observed adverse events is hypertension, which is generally mild to moderate and manageable.12 Is hypertension related to capillary rarefaction in patients receiving anti-VEGF treatments? Could antiangiogenic therapy favor a mismatch between adaptive cardiac hypertrophy and coronary capillary density? Would it accelerate the switch from cardiac hypertrophy to heart failure in treated patients? Would these phenomenons reversible after cessation of the antiangiogenic treatment?The present study by Izumiya et al10 strongly suggests that defects and impairments in the main proangiogenic factors are likely involved in the occurrence of heart failure in a model of pressure overload-induced cardiac hypertrophy. If these finding are confirmed in a clinical setting, VEGF and its receptors could be a new molecular target for treating severe heart failure.Download figureDownload PowerPointProposed mechanisms whereby VEGF may be an obligatory link among myocardial demand, microvascular coronary network, and cardiac hypertrophy or failure.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.This work has been supported by Inserm and Société pour le Développement de la Recherche Cardiovasculaire.FootnotesCorrespondence to Bernard Lévy, Centre for Cardiovascular Research, Inserm U689, 41 Bd de la Chapelle, 75010 Paris, France. E-mail [email protected] References 1 Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438: 932–936.CrossrefMedlineGoogle Scholar2 Hoppeler H. Vascular growth in hypoxic skeletal muscle. Adv Exp Med Biol. 1999; 474: 277–286.CrossrefMedlineGoogle Scholar3 Dunn JF, Grinberg O, Roche M, Nwaigwe CI, Hou HG, Swartz HM. Noninvasive assessment of cerebral oxygenation during acclimation to hypobaric hypoxia. J Cereb Blood Flow Metab. 2000; 20: 1632–1635.CrossrefMedlineGoogle Scholar4 Riddle DR, Sonntag WE, Lichtenwalner RJ. Microvascular plasticity in aging. Ageing Res Rev. 2003; 2: 149–168.CrossrefMedlineGoogle Scholar5 Ruedemann AD. Conjunctival vessels. JAMA. 1933; 101: 1477–1481.CrossrefGoogle Scholar6 Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation. 2001; 104: 735–740.CrossrefMedlineGoogle Scholar7 Serné EH, Gans ROB, ter Maaten JC, ter Wee PM, Donker AJ, Stehouwer CD. Capillary recruitment is impaired in essential hypertension and relates to insulin’s metabolic and vascular actions. Cardiovasc Res. 2000; 49: 161–168.Google Scholar8 Prewitt RL, Hashimoto H, Stacy DL. Structural and functional rarefaction of microvessels in hypertension. In Lee R, ed. Blood Vessels Changes in Hypertension: Structure and Function. Boca Raton, FL: CRC Press; 1990: 71–90.Google Scholar9 Karch R, Neumann F, Ullrich R, Neumuller J, Podesser BK, Neumann M, Schreiner W. The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy. Cardiovascular Pathology. 2005; 14: 135–144.CrossrefMedlineGoogle Scholar10 Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure-overload. Hypertension. 2006; 47: 887–893.LinkGoogle Scholar11 Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005; 115: 2108–2118.CrossrefMedlineGoogle Scholar12 Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005; 69 (Suppl 3): 25–33.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Tocchetti C, Cadeddu C, Di Lisi D, Femminò S, Madonna R, Mele D, Monte I, Novo G, Penna C, Pepe A, Spallarossa P, Varricchi G, Zito C, Pagliaro P and Mercuro G (2019) From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview, Antioxidants & Redox Signaling, 10.1089/ars.2016.6930, 30:18, (2110-2153), Online publication date: 20-Jun-2019. Justice C, Derbala M, Baich T, Kempton A, Guo A, Ho T and Smith S (2018) The Impact of Pazopanib on the Cardiovascular System, Journal of Cardiovascular Pharmacology and Therapeutics, 10.1177/1074248418769612, 23:5, (387-398), Online publication date: 1-Sep-2018. Maurea N, Coppola C and Rienzo A (2017) Changes of Myocardial Structure and Function Anti-Cancer Treatments and Cardiotoxicity, 10.1016/B978-0-12-802509-3.00008-X, (55-72), . Molinaro M, Ameri P, Marone G, Petretta M, Abete P, Di Lisa F, De Placido S, Bonaduce D and Tocchetti C (2015) Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs, BioMed Research International, 10.1155/2015/138148, 2015, (1-14), . Saad A, Herrmann S and Textor S (2015) Chronic Renal Ischemia in Humans: Can Cell Therapy Repair the Kidney in Occlusive Renovascular Disease?, Physiology, 10.1152/physiol.00065.2013, 30:3, (175-182), Online publication date: 1-May-2015. Madonna R, Cadeddu C, Deidda M, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti C, Zito C and Mercuro G (2015) Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection, Heart Failure Reviews, 10.1007/s10741-015-9497-4, 20:5, (621-631), Online publication date: 1-Sep-2015. Qi W, Shen Z, Tang L and Yao Y (2014) Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials, British Journal of Clinical Pharmacology, 10.1111/bcp.12387, 78:4, (748-762), Online publication date: 1-Oct-2014. Tocchetti C, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, Giudice A, Iaffaioli R, Arra C and Maurea N (2014) The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors, European Journal of Heart Failure, 10.1093/eurjhf/hft008, 15:5, (482-489), Online publication date: 1-May-2013. Eirin A and Lerman L (2013) Darkness at the End of the Tunnel: Poststenotic Kidney Injury, Physiology, 10.1152/physiol.00010.2013, 28:4, (245-253), Online publication date: 1-Jul-2013. Grenier J (2012) Complications cardiaques et vasculaires des antiangiogéniques (à l’exception des effets rénaux et des complications hémorragiques)Vascular and cardiac complications of angiogenesis inhibitors (excluding renal effects and hemorrhagic complications), Oncologie, 10.1007/s10269-012-2145-x, 14:4, (237-247), Online publication date: 1-Apr-2012. Yin Z, Fan L, Jia H, Li C, Zhang R and Wang H (2012) S1P1 and S1P3 are potential markers of cardiac microangiopathy in diabetes, Medical Hypotheses, 10.1016/j.mehy.2012.04.025, 79:2, (168-170), Online publication date: 1-Aug-2012. Kelsen S, He X and Chade A (2012) Early superoxide scavenging accelerates renal microvascular rarefaction and damage in the stenotic kidney, American Journal of Physiology-Renal Physiology, 10.1152/ajprenal.00154.2012, 303:4, (F576-F583), Online publication date: 15-Aug-2012. Leonard B, Smaill B and LeGrice I (2012) Structural Remodeling and Mechanical Function in Heart Failure, Microscopy and Microanalysis, 10.1017/S1431927611012438, 18:1, (50-67), Online publication date: 1-Feb-2012. Chade A (2011) Renovascular disease, microcirculation, and the progression of renal injury: role of angiogenesis, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00657.2010, 300:4, (R783-R790), Online publication date: 1-Apr-2011. Fendler J, Malavaud B, Gimel P, Duclos B, Chevreau C and Pignot G (2010) Cancer du rein : traitements anti-angiogéniques et gestion des complications. À propos d’un cas, Progrès en Urologie, 10.1016/S1166-7087(10)70022-1, 20, (S27-S32), Online publication date: 1-Mar-2010. Simon H (2010) Traitement anti-angiogénique du cancer du sein métastatique : gestion des effets secondaires Cancer du sein en situation métastatique, 10.1007/978-2-8178-0076-9_24, (243-256), . Iliescu R, Fernandez S, Kelsen S, Maric C and Chade A (2009) Role of renal microcirculation in experimental renovascular disease, Nephrology Dialysis Transplantation, 10.1093/ndt/gfp605, 25:4, (1079-1087), Online publication date: 1-Apr-2010. Zhu X, Daghini E, Chade A, Napoli C, Ritman E, Lerman A and Lerman L (2007) Simvastatin Prevents Coronary Microvascular Remodeling in Renovascular Hypertensive Pigs, Journal of the American Society of Nephrology, 10.1681/ASN.2006090976, 18:4, (1209-1217), Online publication date: 1-Apr-2007. Schiekofer S, Shiojima I, Sato K, Galasso G, Oshima Y and Walsh K (2006) Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure, Physiological Genomics, 10.1152/physiolgenomics.00234.2005, 27:2, (156-170), Online publication date: 1-Oct-2006. Kirichenko Y, Ilgisonis I, Belenkov Y, Privalova E, Naymann Y, Lyamin A, Kozhevnikova M, Korobkova E, Khabarova N and Ogorodnikov N (2020) The effect of chemotherapy on endothelial function and microcirculation in patients with gastric cancer, Kardiologiia, 10.18087/cardio.2020.2.n908, 60:2, (89-95) Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, Mercurio V, Monte I, Novo G, Parrella P, Pirozzi F, Pecoraro A, Spallarossa P, Zito C, Mercuro G, Pagliaro P and Tocchetti C (2018) Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective, Frontiers in Physiology, 10.3389/fphys.2018.00167, 9 May 2006Vol 47, Issue 5 Advertisement Article InformationMetrics https://doi.org/10.1161/01.HYP.0000215283.53943.39PMID: 16567590 Originally publishedMarch 27, 2006 PDF download Advertisement